Beam Therapeutics is trading at $23.45, down 4.01%, in live trading as hotter-than-expected September core inflation and rising yields weigh on growth-oriented shares.
- Broad market and sector weakness are the clearest context for the decline; major U.S. indexes and biotech are also lower.
- Beam Therapeutics announced initial BEAM-301 data on October 13, but available coverage does not establish the announcement as the cause of this session’s drop.